Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients

Borgmann, H.; Musquera, M.; Haferkamp, A.; Vilaseca, A.; Klatte, T.; Shariat, S.; Scavuzzo, A.; Jimenez Rios, M.; Wolff, I.; Capitanio, U.; Dell'Oglio, P.; Krabbe, L.; Herrmann, E.; Ecke, T.; Vergho, D.; Huck, N.; Wagener, N.; Pahernik, S.; Zastrow, S.; Wirth, M.
December 2017
World Journal of Urology;Dec2017, Vol. 35 Issue 12, p1891
Academic Journal
Purpose: Because the prognostic impact of the clinical and pathological features on cancer-specific survival (CSS) and overall survival (OS) in patients with papillary renal cell carcinoma (papRCC) is still controversial, we want to assess the impact of clinicopathological features, including Fuhrman grade and age, on survival in surgically treated papRCC patients in a large multi-institutional series. Methods: We established a comprehensive multi-institutional database of surgically treated papRCC patients. Histopathological data collected from 2189 patients with papRCC after radical nephrectomy or nephron-sparing surgery were pooled from 18 centres in Europe and North America. OS and CSS probabilities were estimated using the Kaplan-Meier method. Multivariable competing risks analyses were used to assess the impact of Fuhrman grade (FG1-FG4) and age groups (<50 years, 50-75 years, >75 years) on cancer-specific mortality (CSM). Results: CSS and OS rates for patients were 89 and 81% at 3 years, 86 and 75% at 5 years and 78 and 41% at 10 years after surgery, respectively. CSM differed significantly between FG 3 (hazard ratio [HR] 4.22, 95% confidence interval [CI] 2.17-8.22; p < 0.001) and FG 4 (HR 8.93, 95% CI 4.25-18.79; p < 0.001) in comparison to FG 1. CSM was significantly worse in patients aged >75 (HR 2.85, 95% CI 2.06-3.95; p < 0.001) compared to <50 years. Conclusions: FG is a strong prognostic factor for CSS in papRCC patients. In addition, patients older than 75 have worse CSM than patients younger than 50 years. These findings should be considered for clinical decision making.


Related Articles

  • Size of localized renal cell carcinoma is important prognostic factor. Hiroš, Mustafa; Hasanbegović, Munira; Spahović, Hajrudin; Selimović, Mirsad; Sadović, Sabina // Medical Journal;Apr-Jun2015, Vol. 21 Issue 2, p118 

    Tumor size is one of the most important prognostic factors of renal cell carcinoma (RCC) and the mainstay of TNM classification in case of a localized tumor. The objective of this study was to validate the prognostic value of the tumor size and localization in the primary tumor of patients with...

  • Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. Krabbe, Laura-Maria; Haddad, Ahmed; Westerman, Mary; Margulis, Vitaly // World Journal of Urology;Jun2014, Vol. 32 Issue 3, p615 

    Background: Cytoreductive nephrectomy (CN) has been considered standard management for patients with metastatic renal cell carcinoma (mRCC) for over a decade. This practice, based on evidence from the immunotherapy era, has now come into question with the dramatic shift in management of mRCC...

  • Hematuria following kidney tumorectomy: can it hide an arteriovenous fistula? Pavan, Nicola; Liguori, Giovanni; Vedovo, Francesca; Bucci, Stefano; Bertolotto, Michele; Trombetta, Carlo // Urologia;Jul-Sep2015, Vol. 82 Issue 3, p191 

    We present the case and radiologic images of a 64-year-old man who presented with gross hematuria and fever 2 months after undergoing retroperitoneal partial nephrectomy for a 4.7 × 4.6 cm papillary renal cell carcinoma. Angio- TC demonstrated an aneurysmatic dilatation of the anterior...

  • Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients. Dielmann, Anastasia; Letsch, Anne; Nonnenmacher, Anika; Miller, Kurt; Keilholz, Ulrich; Busse, Antonia // Cancer Immunology, Immunotherapy;Feb2016, Vol. 65 Issue 2, p181 

    T-box transcription factors, T-box expressed in T cells (T-bet) encoded by Tbx21 and Eomesodermin (Eomes), drive the differentiation of effector/memory T cell lineages and NK cells. The aim of the study was to determine the prognostic influence of the expression of these transcription factors in...

  • Renal tumor size is an independent prognostic factor for overall survival in von Hippel-Lindau disease. Kwon, Taekmin; Jeong, In; Pak, Sahyun; You, Dalsan; Song, Cheryn; Hong, Jun; Ahn, Hanjong; Kim, Choung-Soo // Journal of Cancer Research & Clinical Oncology;Jul2014, Vol. 140 Issue 7, p1171 

    Objectives: To evaluate the effect of renal cell carcinoma (RCC) on survival in von Hippel-Lindau (VHL) disease and to assess the relationship between tumor size and survival. Materials and methods: In this retrospective cohort study, the medical records of 72 patients who presented with VHL...

  • mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma. Bailey, Sean T.; Zhou, Bing; Damrauer, Jeffrey S.; Krishnan, Bhavani; Wilson, Harper L.; Smith, Aleisha M.; Li, Mingqing; Yeh, Jen Jen; Kim, William Y. // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus...

  • Angiotensin system inhibitors extended PFS, OS in renal cell carcinoma.  // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p24 

    The article discusses research being done on the use of angiotensin system inhibitors in patients with renal cell carcinoma, which references a study by Rana McKay et al. presented at the 2014 Genitourinary Cancers Symposium in San Francisco, California.

  • Addition of nivolumab to sunitinib or pazopanib induced response in mRCC. Adams, Stacey; Southall, Jennifer; Todak, Alexandra // Hem/Onc Today;7/25/2014, Vol. 15 Issue 14, p19 

    The article discusses a study which concluded that the programmed cell death-1 (PD1) immune check point inhibitor antibody nivolumab in combination with either sunitinib or pazopanib yields antitumor activity with manageable toxicity in patients of metastatic renal cell carcinoma.

  • The role of renal surgery in the era of targeted therapy: the urologist's perspective. Battaglia, Michele; Lucarelli, Giuseppe // Urologia;Jul-Sep2015, Vol. 82 Issue 3, p137 

    Renal cell carcinoma (RCC) is increasingly diagnosed at an early stage in many countries, which has likely contributed to the recent leveling of RCC mortality. Nevertheless, despite these advances in diagnosis, up to 30% of patients have metastatic RCC at the time of diagnosis, and around 20-30%...

  • RHABDOID VARIANT OF CLEAR CELL RENAL CELL CARCINOMA- A CASE REPORT. Ahmed, Rabia; Hafeez Ud Din; Shoaib Naiyar Hashmi // Pakistan Armed Forces Medical Journal;Jun2015, Vol. 65 Issue 3, p432 

    The article presents a case study of a 62 years old male who was admitted to the Armed Forces Institute of Urology due to aching pain in both flanks specially on right side. Topics discussed include Rhabdoid Variant Renal Cell Carcinoma, presence of adult clear cell renal cell carcinoma with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics